Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
The Regulatory Affairs Team Leader will lead the Regulatory Team for CCTG within the OCO. The core responsibilities include leadership to ensure compliance with national and international regulations essential to the compliant conduct of clinical trials, development and implementation of Standard Operating Procedures at the Operations and Statistics Centre at Queen's University and in support of partnering organizations, and providing guidance in alignment with CCTG strategic directions.
The CCTG Pharmacy Network is actively seeking pharmacy representation for a pharmacist representative for the Genitourinary Disease Site Committee and a pharmacist representative for the Steering Group from Quebec.
CCTG is hiring right now for several positions including; Clinical Trial Assistants, Study Coordinators and a Clinical Research Associate. The positions are open at the CCTG Central Operations and Statistics Office located at Queen's University in Kingston, Ontario. For more information about the current career opportunities with us please visit our Careers Page.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
With sorrow, CCTG would like to note the recent passing of Dr. David Osoba.
A look back at 2020, a pandemic year that saw tremendous achievements across the CCTG network
This past year has been one of constant challenge within our group, network, country, and the world. Yet despite the disruptions to our daily lives and work, this year has also been one of immense accomplishment.
PR21 A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease has been centrally activated.
Holiday hours and days of operation for the CCTG central office, CCTG’s Tumour Tissue Data Repository and the Bay Area Research Logistics.
